Serum ATX as a novel biomarker for breast cancer
Open Access
- 1 March 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 98 (13) , e14973
Abstract
Recent accumulating evidence indicates the biological actions of Autotaxin-Lysophosphatidic acid (ATX-LPA) signaling axis in malignant tumors. However, the role of Autotaxin-Lysophosphatidic acid signaling axis in breast cancer has not been reported. The present study aims to examine the alterations of serum autotaxin in breast cancer and discuss whether serum autotaxin could be useful as a novel parameter of breast cancer. Serum autotaxin antigen was measured in 112 patients with breast cancer and 50 healthy volunteers by ELISA. The association of serum autotaxin antigen levels with clinicopathological parameters and outcomes of breast cancer was analyzed. Serum autotaxin antigen was significantly higher in breast cancer patients than healthy volunteers (291.32 ± 38.02 ng/ml vs 254.04 ± 21.03 ng/ml, respectively; P < .0001). Serum autotaxin measurement successfully discriminated breast cancer patients from normal and healthy controls (AUC = 0.798, 95% CI: 0.732–0.864) with an optimal cut-off value of 267.34 ng/ml (sensitivity = 0.741, specificity = 0.800). Increased serum autotaxin was associated with breast cancer nodal status (P = .007), Tumor-Node- Metastasis (TNM) stage (P = .009) and Ki-67 index (P = .004). Univariate and multivariate Cox regression analysis revealed that elevated serum autotaxin showed an independent prognostic value for poor Disease-free survival. Our present study confirmed the elevation, potential diagnostic, and independent prognostic value of serum autotaxin for breast cancer. Serum autotaxin could serve as a reliable novel biomarker for breast cancer.Keywords
This publication has 23 references indexed in Scilit:
- Breast cancer statistics, 2017, racial disparity in mortality by stateCA: A Cancer Journal for Clinicians, 2017
- Breast cancer in Egypt, China and Chinese: statistics and beyond2014
- Gene expression profiling in breast cancer: classification, prognostication, and predictionThe Lancet, 2011
- ATX–LPA Axis Induces Expression of OPN in Hepatic Cancer Cell SMMC7721The Anatomical Record, 2010
- LPA Receptors: Subtypes and Biological ActionsAnnual Review of Pharmacology and Toxicology, 2010
- ATX-LPA receptor axis in inflammation and cancerCell Cycle, 2009
- Breast cancer prognostication and prediction: are we making progress?Annals of Oncology, 2007
- Regulation and biological activities of the autotaxin–LPA axisProgress in Lipid Research, 2007
- Identification of Human Plasma Lysophospholipase D, a Lysophosphatidic Acid-producing Enzyme, as Autotaxin, a Multifunctional PhosphodiesteraseJournal of Biological Chemistry, 2002
- Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid productionJournal of Cell Biology, 2002